Appearances

• Guidelines lipid-lowering in the elderly present and future view
• Transforming Atherosclerosis Regression into an Endpoint that the EMA and FDA Could Approve
• How to Decide Whether to Add the Next Drug?
• Precision Medicine- Helpful or Hype?
• Lipid Management and Aging (AHA/National Lipid Association Joint Session)
• One Size Doesn't Fit All-- Difficult Decisions in Prevention Practice
• Eradicating Atherosclerotic CVD: New Drugs for Reducing ApoB-Containing Lipoproteins
• Going Boldly Beyond: Further LDL Lowering With PCSK9 and Non-Statins
• Clinical Lipidology Update
• Late Breaking Clinical Trial: Answers to Critical Questions in Cardiovascular Prevention
• Clinical Lipidology Update
• Add on Lipid Therapy How Do We Decide?
• Prevention Beyond the Guidelines: What to Do Next
• Bang for Your Buck: Role of Value in the Adoption of New Therapies
• Adopting New Pharmacotherapies: When It Goes Well, When it Doesn't and Why?
• Discussant: EWTOPIA75
• Statin Intolerance: Recent Insights
• Gaps in the 2018 Cholesterol Guidelines: The Great Debate(s)
• What to Do Next? Moving from Risk to Benefit in Guidelines
• SecondaryPrevention: NNT & NNH to Estimate Net Benefit From LDL-C Lowering Drugs
• SecondaryPrevention: PCSK9i